Research On The Development Direction Of Chinese Pharmaceutical Enterprises

Pharmaceutical enterprise is closely related to people’s life, as long as life rest, the development of pharmaceutical enterprises will never stop. Due to human appear constantly in the process of survival and development of the difficult problems, prompting medicine study on science and technology enterprises. Pharmaceutical enterprise, therefore, is a continuous rising sun industry, the endless, but at the same time for pharmaceutical enterprise is a relationship to the big industry of national economy and people’s livelihood, decide it is a high technology, high risk industry. In the past two years, with the rapid development of China’s economy, the pharmaceutical enterprises in our country has got unprecedented development. Our country medicine enterprise overall presented six trends: proprietary Chinese medicine market competition will aggravate; Prescription drug life cycle will be shortened; The third terminal market will be more active; Medical market concentration, further medical polarization further highlight; Policy prices will continue; Varieties of structure adjustment further acceleration, the enterprises market structure will change more. As the industry competition, pharmaceutical enterprises feel the unprecedented pressure compared with other national pharmaceutical companies, pharmaceutical companies in our country in such aspects as technology, capital,management, there is still a large gap, the pharmaceutical enterprises in our country still stays in the predominantly imitation stage, it’s not good for future development, will cause our country medicine brand general lack of competitiveness in the international market, is difficult to realize the Chinese medicine brand in the world.This article from the internal and external environment for the development of pharmaceutical enterprises in detail analysis, for example demonstrated use, data, software, the instruction method, aimed at establishing enterprise development target for pharmaceutical enterprise managers, strategic, and government policy for reference to guide the industry development.